Fluticasone furoate/umeclidinium bromide/vilanterol
Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[2][3] It is inhaled.[4][5][6]
Combination of | |
---|---|
Fluticasone furoate | Corticosteroid |
Umeclidinium bromide | Muscarinic antagonist |
Vilanterol | Ultra-long-acting β2 agonist |
Clinical data | |
Trade names | Trelegy Ellipta, Elebrato Ellipta, Temybric Ellipta |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a618017 |
License data |
|
Pregnancy category | |
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
KEGG |
History
Fluticasone furoate/umeclidinium bromide/vilanterol was approved for use in the United States in September 2017.[2] It was approved for use in the European Union in November 2017.[7][6][8]
References
- "Fluticasone / umeclidinium / vilanterol (Trelegy Ellipta) Use During Pregnancy". Drugs.com. 13 June 2019. Retrieved 4 February 2020.
- "Trelegy Ellipta (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg) Inhalation Powder". U.S. Food and Drug Administration (FDA). 20 February 2018. Retrieved 4 February 2020.
- Lipson DA, Barnhart F, Brealey N, et al. (May 2018). "Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD". N. Engl. J. Med. 378 (18): 1671–1680. doi:10.1056/NEJMoa1713901. PMID 29668352.
- "Trelegy Ellipta- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 15 May 2019. Retrieved 4 February 2020.
- "Fluticasone, Umeclidinium, and Vilanterol (Professional Patient Advice)". Drugs.com. 25 November 2019. Retrieved 4 February 2020.
- "Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 30 October 2019. Retrieved 4 February 2020.
- "Trelegy Ellipta EPAR". European Medicines Agency (EMA). 24 May 2019. Retrieved 4 February 2020.
- "Elebrato Ellipta EPAR". European Medicines Agency (EMA). Retrieved 19 June 2020.
External links
- "Fluticasone furoate mixture with umeclidinium and vilanterol". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.